 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | isuzinaxib (APX-115) / AptaBio
Trial completion date: A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19. (clinicaltrials.gov) - Jul 20, 2023
P2, N=80, Recruiting, Sponsor: Aptabio Therapeutics, Inc.
Trial completion date: Mar 2023 --> Sep 2023
- APX-115 / AptaBio
Effect of Isuzinaxib, Pan NOX Inhibitor in Patients With Type 2 Diabetes and CKD in a Randomized, Double Blind, Placebo Controlled Phase 2 Trial (W415 Valencia, Orange County Convention Center‚ West Building) - Oct 15, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_4529;
P2
Funding Commercial Support Background Isuzinaxib (APX-115), a novel inhibitor of pan NOX; oxidative stress modulator was investigated a kidney outcome in patients with type 2 diabetes (T2DM) and chronic kidney disease (CKD) compared with Placebo...Conclusion Isuzinaxib resulted in anti-albuminuric effect and was safe and well tolerable in patients with T2DM and CKD. The results demonstrate first clinical evidence by NADPH oxidase (NOX) inhibitors contributing to oxidative stress in patients with T2DM and CKD.
- ||| isuzinaxib (APX-115) / AptaBio
Enrollment open, Trial completion date, Trial primary completion date: A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19. (clinicaltrials.gov) - Sep 28, 2021
P2, N=80, Recruiting, Sponsor: Aptabio Therapeutics, Inc.
The results demonstrate first clinical evidence by NADPH oxidase (NOX) inhibitors contributing to oxidative stress in patients with T2DM and CKD. Not yet recruiting --> Recruiting | Trial completion date: Mar 2022 --> Mar 2023 | Trial primary completion date: Feb 2022 --> Feb 2023
- | isuzinaxib (APX-115) / AptaBio
Trial completion: Safety, Tolerability and Renal Effects of APX-115 in Subjects With Type 2 Diabetes and Nephropathy (clinicaltrials.gov) - Aug 25, 2021
P2, N=140, Completed, Sponsor: Aptabio Therapeutics, Inc.
Not yet recruiting --> Recruiting | Trial completion date: Mar 2022 --> Mar 2023 | Trial primary completion date: Feb 2022 --> Feb 2023 Active, not recruiting --> Completed
- | APX-115 / AptaBio
Journal: The NADPH oxidase family and its inhibitors. (Pubmed Central) - Aug 21, 2021
Several of these new molecules are potent and very specific inhibitors that could be good candidates for the development of new drugs. Even if the results are very promising, most of these compounds were only validated in vitro or in mice models and further investigations will be required before using them as potential therapies.
- APX-115 / AptaBio
[VIRTUAL] APX-115 against diabetic kidney disease: from bench to phase II clinical trial (Room 1) - Aug 20, 2021 - Abstract #KSN2021KSN_142;
- | APX-115 / AptaBio
Preclinical, Journal: APX-115, a pan-NADPH oxidase inhibitor, protects development of diabetic nephropathy in podocyte specific NOX5 transgenic mice. (Pubmed Central) - Jun 22, 2021
Moreover, APX-115 inhibited the expression of inflammation-related proteins such as TRAF6. Collectively, these data suggest that APX-115 might be a promising therapeutic agent for the treatment of DN because of its pan-NOX inhibitory activity, including its NOX5 inhibitory activity, and also owing to its anti-inflammatory effects.
- |||| isuzinaxib (APX-115) / AptaBio
New P2 trial: A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19. (clinicaltrials.gov) - May 9, 2021
P2, N=80, Not yet recruiting, Sponsor: Aptabio Therapeutics, Inc.
- | isuzinaxib (APX-115) / AptaBio
Enrollment closed: Safety, Tolerability and Renal Effects of APX-115 in Subjects With Type 2 Diabetes and Nephropathy (clinicaltrials.gov) - May 6, 2021
P2, N=140, Active, not recruiting, Sponsor: Aptabio Therapeutics, Inc.
Collectively, these data suggest that APX-115 might be a promising therapeutic agent for the treatment of DN because of its pan-NOX inhibitory activity, including its NOX5 inhibitory activity, and also owing to its anti-inflammatory effects. Recruiting --> Active, not recruiting
- | isuzinaxib (APX-115) / AptaBio
New P2 trial: Safety, Tolerability and Renal Effects of APX-115 in Subjects With Type 2 Diabetes and Nephropathy (clinicaltrials.gov) - Aug 31, 2020
P2, N=140, Recruiting, Sponsor: Aptabio Therapeutics, Inc.
- | isuzinaxib (APX-115) / AptaBio
Trial completion: Safety, Tolerability, PK and PD of SAD or MAD of APX-115 in Healthy Male Volunteers (clinicaltrials.gov) - Mar 11, 2019
P1, N=88, Completed, Sponsor: Aptabio Therapeutics, Inc.
Recruiting --> Active, not recruiting Recruiting --> Completed
- | isuzinaxib (APX-115) / AptaBio
New P1 trial: Safety, Tolerability, PK and PD of SAD or MAD of APX-115 in Healthy Male Volunteers (clinicaltrials.gov) - Oct 2, 2018
P1, N=88, Recruiting, Sponsor: Aptabio Therapeutics, Inc.